» Articles » PMID: 1430094

Suppression of Human Spermatogenesis by Testosterone Implants

Overview
Specialty Endocrinology
Date 1992 Nov 1
PMID 1430094
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Hormonally induced azoospermia is an effective, reversible form of male contraception; however, some men treated with weekly im testosterone enanthate (TE) injections fail to become azoospermic. As weekly injections cause widely fluctuating and supraphysiological testosterone levels, we tested the hypothesis that more stable, physiological testosterone levels would consistently produce azoospermia. Using a depot testosterone formulation which provides stable, physiological range testosterone levels for up to 6 months, we studied nine men before and after insertion of six 200 mg testosterone implants under the abdominal wall skin and compared the results with 38 men treated in a previous study with weekly im injections of 200 mg TE. Testosterone implants suppressed sperm output to near-azoospermia between the second to fourth postimplant months returning to normal by the sixth postimplant month. The fall in sperm output at the first month was greater after testosterone implants than TE injections (58% vs. 17%, P = 0.011) but similar proportions of men became azoospermic (5/9 vs. 25/38) or severely oligozoospermic (< 1 million/ml; 9/9 vs. 37/38). Plasma testosterone and estradiol levels remained mostly within the eugonadal range after implants but were markedly supraphysiological during TE injections. Both treatments suppressed immunoreactive LH and FSH to undetectable levels by ultrasensitive fluoroimmunoassay. Sex hormone-binding globulin levels were decreased and PRL levels increased by TE injections but neither was changed by testosterone implants. Prostate-specific antigen demonstrated a small rise of marginal significance (P = 0.065) after testosterone implants. Fewer men experienced acne after implants (0/9 vs. 25/38, p = 0.0004). Therefore a depot testosterone preparation with quasi-zero-order release demonstrates higher dose efficiency with similar (but not uniform) efficacy at inducing azoospermia but may cause fewer androgenic side-effects than weekly TE injections.

Citing Articles

Male contraception: narrative review of ongoing research.

Louwagie E, Quinn G, Pond K, Hansen K Basic Clin Androl. 2023; 33(1):30.

PMID: 37940863 PMC: 10634021. DOI: 10.1186/s12610-023-00204-z.


Vasectomy reversal outcomes in men after testosterone therapy.

Bash J, Lo J, Kapadia A, Mason M, Hedges J Sci Rep. 2022; 12(1):19496.

PMID: 36376515 PMC: 9663445. DOI: 10.1038/s41598-022-22823-8.


The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Alemany M Int J Mol Sci. 2022; 23(19).

PMID: 36233256 PMC: 9569951. DOI: 10.3390/ijms231911952.


Clinical Evaluation of the Spermatogenic Activity of the Root Extract of Ashwagandha (Withania somnifera) in Oligospermic Males: A Pilot Study.

Ambiye V, Langade D, Dongre S, Aptikar P, Kulkarni M, Dongre A Evid Based Complement Alternat Med. 2013; 2013:571420.

PMID: 24371462 PMC: 3863556. DOI: 10.1155/2013/571420.


A role for nocturnal serum testosterone surge in regulating spermatogenesis in the adult non-human primate.

Suresh R, Moudgal N Endocrine. 2010; 3(7):487-92.

PMID: 21153203 DOI: 10.1007/BF02738822.